Drugs / TY-1091
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05675605 | Apr 2023 → Jun 2025 | medullary thyroid gland carcinoma, non-small cell lung carcinoma, thyroid gland papillary carcinoma | TYK Medicines, Inc | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TY-1091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05675605 ↗ |
| Route | Oral | “oral administration” NCT05675605 ↗ |